RBC Capital Markets BioTech Analyst Michael Yee and CastleArk Management President & CIO Jerry Castellini discuss the bull and bear cases for biotech stocks.» Read More
Michel Demaré, chairman of Syngenta, says the takeover deal with state-owned ChemChina is good value for shareholders.
Pacific Biosciences shares were trading up 25 percent at $12.70 in afternoon trading in New York on the news, giving the company a market value of close to $1 billion. Based in Menlo Park, California, Pacific Biosciences focuses primarily on developing and manufacturing systems for gene sequencing. In 2013, Roche, which is based in Basel, Switzerland, penned a...
Regulators warn that new Theranos lab in California is unsafe for patients, company says it's taking corrective action. CNBC's Meg Tirrell explains.
After rash of earnings reports, Abbott Labs, Bristol-Myers Squibb, Celgene and Eli Lilly shares suffer. CNBC's Meg Tirrell reports.
*Worsening response rates observed in patients receiving drug. Jan 25- OncoMed Pharmaceuticals Inc lost nearly half its market value after independent investigators informed the company that its pancreatic cancer drug was unlikely to meet the main goal in a mid-stage study. The setback sent the company's shares down by as much 46 percent to a record-low of...
JMP Securities President Mark Lehmann explains why now is the time to get in on biotech stocks.
Celgene's Mark Hugin is replaced by Mark Alles as CEO, and the company lowers earnings estimates, reports CNBC's Sue Herera.
Novartis CEO Joe Jimenez says the pharma industry needs to rethink pricing as drug combinations are increasingly being used to treat cancer and other diseases.
Eli Lilly's John Lechleiter says he's optimistic about the year ahead for the pharmaceuticals industry, including measures to help patients afford prescription drugs.
Eli Lilly CEO John Lechleiter discusses clinical trials of his company's treatments for Alzheimer's disease.
Activist investor Bill Ackman's Pershing Square Capital Management is cutting its stake in Valeant Pharmaceuticals, reports CNBC's Seema Mody.
A Chinese firm that's building the world's biggest animal cloning factory has vowed not to use the technology on people—for now. NBCNews reports.
Nov 18- StemCells Inc said its experimental stem cell therapy improved the functioning and strength of limbs in patients with spinal cord injuries, becoming the second company to report promising data on the treatment for such injuries. StemCells' research centers around the treatment for spinal cord injuries, visual problems that begin at the retina and...
GlaxoSmithKline CEO Sir Andrew Witty discusses the drug environment as pressure mounts over higher prices.
GlaxoSmithKline CEO Sir Andrew Witty weighs in on why his company has no immediate deal plans in the drug space.
U.S. prosecutors are probing Valeant Pharmaceuticals over how it prices and distributes drugs, the Canadian pharma giant revealed late Wednesday.
And artificial intelligence will be hot for Chinese consumers, but 3-D printing will be all the rage in Europe.
James West, senior healthcare analyst for Results Healthcare, talks about biotech stocks and explains the differences biotech and pharmaceutical companies.
Bill Doyle, Executive Chairman, NovoCure, discusses the company's difficult debut--shares opened at $20.16, below the $22 IPO price.
With health care, financials and energy sectors all embattled, what should investors expect going into the fourth quarter and 2016?